Catalent Pharma Solutions Plans Additional Expansion At Its Winchester, Kentucky, Production Campus
During the recently completed project, Catalent created 140 full-time jobs and invested $52 million to add 80,000 square feet to its 100,000-square-foot facility on Enterprise Drive. The new $62-million investment, announced today, will be used to create additional square footage and renovate existing space for new equipment. Catalent plans to hire up to 300 workers, including military veterans, over the next five years.
“The Winchester facility has grown through continued investment in technical expertise and capability, an achievement made possible through our associates at Winchester,” said Barry Littlejohns, Catalent’s president of Advanced Delivery Technologies. “Our success spans many significant product launches, some of which are potentially life-saving drugs. We have a flexible business model that supports tailored solutions for our customers and that is of enduring appeal, driving increased demand for our Winchester manufacturing services and attracting both new and existing partners to manufacture.”
As an incentive to encourage the new investment and job growth in Winchester, the Kentucky Economic Development Finance Authority preliminarily approved the company for tax incentives up to $4.5 million through the Kentucky Business Investment program. The performance-based incentive allows a company to keep a portion of its investment over the term of the agreement through corporate income tax credits and wage assessments by meeting job and investment targets.
KEDFA also approved Catalent for tax benefits up to $700,000 through the Kentucky Enterprise Initiative Act, which allows approved companies to recoup Kentucky sales and use tax on construction costs, building fixtures, equipment used in research and development and electronic processing equipment.
Catalent is the leading global provider of advanced drug delivery technologies and development solutions for drugs, biologics and consumer health products. Opened in 1992, the Winchester plant currently employs more than 500 people and produces a variety of over-the-counter and prescription drugs in tablets, capsules and powders. The facility has launched more than 100 products for Catalent’s pharmaceutical and consumer health customers.
“Between these two investments, Catalent is to create up to 450 jobs and is investing $114 million in central Kentucky,” said Governor Steve Beshear. “We are excited that Catalent, a worldwide leader in pharmaceutical development, continues to grow its operation here, and we look forward to working with the company for many years to come.”
“Catalent’s decision to grow its Kentucky footprint is fantastic news, especially when you consider the impact of the 450 full-time jobs it is bringing to the region,” said Lt. Gov. Luallen. “Kentucky is proud to have Catalent choose Winchester for this opportunity, and we wish the company continued success and prosperity.”
Why are Foreign Trade Zones Making a Comeback?
The New Normal in the Automotive Supply Chain
2020 Auto/Aero Site Guide
34th Annual Corporate Survey & the 16th Annual Consultants Survey
Infrastructure Investment as an Economic Stimulus Tool
Nondisclosure Agreements Best Practices When Negotiating Incentives
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row